Type 5 phosphodiesterase inhibition in heart failure and pulmonary hypertension.

被引：20

作者：

Lewis G.D. ^{[1
]}

Semigran M.J. ^{[1
]}

机构：

[1] Cardiology Division, Massachusetts General Hospital, Fruit Street, Boston, 02114, MA

来源：

Current Heart Failure Reports | 2004年 / 1卷 / 4期

关键词：

Nitric Oxide; Pulmonary Hypertension; Erectile Dysfunction; Pulmonary Arterial Hypertension; Pulmonary Vascular Resistance;

D O I：

10.1007/s11897-004-0007-6

中图分类号：

学科分类号：

摘要：

The availability of selective inhibitors of the cyclic guanosine monophosphate (cGMP)-specific type 5 phosphodiesterase (PDE5) has created increasing interest in unlocking the therapeutic potential of PDE5 inhibition in cardiovascular diseases that are marked by dysfunction of nitric oxide (NO)-cGMP signaling. Pulmonary arterial hypertension (PAH) and heart failure (HF) are characterized by pulmonary arterial vasoconstriction that is thought to be caused by relative deficiencies of vasodilators such as NO and exaggerated production of vasoconstrictors such as endothelin. PDE5 is abundant in the pulmonary vasculature where it catabolizes cGMP, the second messenger of NO. Inhibition of PDE5 has been shown to lower pulmonary vascular resistance in PAH and HF by augmenting local cGMP. This review outlines the therapeutic potential of PDE5 inhibition for the treatment of PAH and HF.

引用

页码：183 / 189

页数：6

共 154 条

[1]

Beavo JA(1995)Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms Physiol Rev 75 725-748

[2]

Wallis RM(1999)Tissue distribution of phosphodiesterase families and the effect of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro Am J Cardiol 83 3C-12C

[3]

Corbin JD(2003)Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system Mol Pharmacol 64 533-546

[4]

Francis SH(2003)Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease Circulation 108 239-244

[5]

Maurice DH(1962)Adenosine 3’5’-phosphate in biological materials J Biol Chem 237 1244-1250

[6]

Palmer D(2002)Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil: review of the literature Eur J Med Res 7 435-446

[7]

Tilley DG(1997)Primary pulmonary hypertension N Engl J Med 336 111-117

[8]

Reffelmann T(2001)Invited review: cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression J Appl Physiol 91 1421-1430

[9]

Kloner RA(1999)Inhaled nitric oxide: basic biology and clinical applications Anesthesiology 91 1090-1121

[10]

Butcher RW(1994)Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors Am J Physiol 266 L536-L543

← 1 2 3 4 5 6 7 8 9 10 →